Nexthera Capital LP Decreases Stake in Abeona Therapeutics Inc. (ABEO)
Nexthera Capital LP lowered its position in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 28.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 354,000 shares of the biopharmaceutical company’s stock after selling 140,064 shares during the period. Abeona Therapeutics accounts for about 1.0% of Nexthera Capital LP’s investment portfolio, making the stock its 23rd largest holding. Nexthera Capital LP owned about 0.88% of Abeona Therapeutics worth $2,266,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in ABEO. Bank of New York Mellon Corp raised its position in shares of Abeona Therapeutics by 125.8% in the 1st quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 23,358 shares in the last quarter. Private Advisor Group LLC grew its stake in shares of Abeona Therapeutics by 50.0% in the 1st quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 6,999 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Abeona Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 204,590 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 30,300 shares during the last quarter. Laurion Capital Management LP purchased a new stake in shares of Abeona Therapeutics in the 1st quarter worth approximately $277,000. Finally, Geode Capital Management LLC grew its stake in shares of Abeona Therapeutics by 2.4% in the 1st quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 4,588 shares during the last quarter. 38.38% of the stock is owned by hedge funds and other institutional investors.
Abeona Therapeutics Inc. (NASDAQ:ABEO) traded up 3.885% during mid-day trading on Thursday, hitting $18.076. The company had a trading volume of 579,399 shares. The company has a 50 day moving average of $13.40 and a 200 day moving average of $8.08. The firm’s market capitalization is $728.23 million. Abeona Therapeutics Inc. has a 1-year low of $4.05 and a 1-year high of $18.90.
Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The firm had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.21 million. Analysts predict that Abeona Therapeutics Inc. will post ($0.68) earnings per share for the current fiscal year.
Several analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research note on Monday, September 18th. Royal Bank Of Canada assumed coverage on Abeona Therapeutics in a research note on Thursday, September 14th. They issued an “outperform” rating and a $23.00 price target on the stock. Maxim Group set a $17.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 29th. BidaskClub upgraded Abeona Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 12th. Finally, Zacks Investment Research upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $18.50.
TRADEMARK VIOLATION NOTICE: “Nexthera Capital LP Decreases Stake in Abeona Therapeutics Inc. (ABEO)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/10/05/nexthera-capital-lp-decreases-stake-in-abeona-therapeutics-inc-abeo.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.